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http://dx.doi.org/10.1016/j.pedneo.2Introduction: Dietary supplementation with probiotics alters intestinal microflora of children
and may have immunomodulatory effects in prevention of allergic diseases. The aim of this
study was to evaluate the effects of Lactobacillus paracasei (LP), strain HF.A00232, as a sup-
plementary agent to levocetirizine in treating children with perennial allergic rhinitis (AR).
Methods: This study was a 12-week, double-blind, randomized, placebo-controlled trial. Sixty
children with AR aged 6e13 years with nasal total symptoms score (NTSS) 5 who fulfilled the
inclusion criteria were enrolled. Patients were randomized into two groups with 28 partici-
pants receiving levocetirizine plus placebo and 32 participants receiving regular levocetirizine
plus LP (HF.A00232) for the first 8 weeks, with a shift to levocetirizine as rescue treatment dur-
ing the following 4 weeks. Parameters evaluated, including nasal, throat, and eye TSS (NTSS,
TTSS, and ETSS, respectively), TSS and levocetirizine use, were recorded daily. Physical exam-
inations and Pediatric Rhinoconjunctivitis Quality of Life Questionnaires (PRQLQs) were admin-
istered at each visit. In addition, blood samples were obtained for evaluation of cytokines
including interleukin-4, interferon-g, interleukin-10, and transforming growth factor-b at
baseline, Week 8, and Week 12.mmunology and Nephrology, Department of Pediatrics, Taichung Veterans General Hospital, Number
chung City 40705, Taiwan.
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182 W.-Y. Lin et alResults: The LP (HF.A00232) group had significantly lower PRQLQ scores even after discontinu-
ing regular levocetirizine from Week 9 to Week 12 (p < 0.01). There was more improvement in
individual parameters in the PRQLQ, including sneezing (p Z 0.005), itchy nose (p Z 0.040),
and swollen puffy eyes (p Z 0.038), in the LP (HF.A00232) group. No significant differences
in TSS, NTSS, TTSS, ETSS, or cytokine levels were found between the two groups.
Conclusion: Dietary supplementation with LP (HF.A00232) provided no additional benefit when
used with regular levocetirizine in treating AR in the initial 8 weeks of our study, but there was
a continuing decrease in PRQLQ scores, as well as a significant improvement in individual symp-
toms of sneezing, itchy nose, and swollen eyes, after discontinuing regular levocetirizine treat-
ment.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
More than 30% of the world’s population is affected by
atopy. The prevalence of atopic diseases such as allergic
rhinitis (AR) and asthma has been increasing in the past 20
years.1 The prevalence of AR among school children aged
6e8 years in Changhua County in central Taiwan has been
reported to be 24.6%.2 An increase in the prevalence of AR
symptoms was reported in 51% of 13- and 14-year-old
children in Taipei, Taiwan, during a 7-year period.3 Several
medical agents are available for treatment of AR, yet there
is still a need for new therapeutic modalities. Interest in
probiotics is increasing because they are widely available
and have minimal adverse effects. Probiotics were defined
by the United Nation’s Food and Agricultural Organization
and the World Health Organization as “live microorganisms
which when administered in adequate amounts confer a
health benefit on the host”.4 These microorganisms have
the potential to modulate mucosal immune response and
subsequently reduce gastrointestinal inflammation caused
by a variety of infectious and allergic triggers.
The most widely studied genera of probiotics and those
more often associated with protection from allergy are the
Lactobacillus and Bifidobacterium species.5,6 Some studies
have evaluated the effect of probiotics on atopic diseases
including AR and asthma, whereas other studies have re-
ported improved symptoms and quality of life scores, less
frequent occurrence of AR episodes, and altered levels of
cytokines such as interleukin (IL)-10, IL-12, transforming
growth factor-b (TGF-b), and interferon-g (IFN-g).5e12
However, substantial heterogeneity in outcome measures
between these studies has precluded conclusive results.
Moreover, several studies that demonstrated efficacy of
probiotics have been criticized because of methodological
flaws and overinterpretation of data; thus, further clinical
trials are needed prior to when firm recommendations can
be made.13
It has been reported that the species Lactobacillus
paracasei (LP) might improve the quality of life of adoles-
cents with perennial AR and even serve as an alternative
treatment.14,15 An in vitro study showed that L. paracasei,
strain HF.A00232, possesses immunomodulatory effects in
decreasing Immunoglobulin E (IgE) and enhancing IFN-g
secretion (unpublished animal study). The present study
was conducted to assess the efficacy of LP (HF.A00232) as asupplementary agent to levocetirizine in improving the
symptoms and cytokine profiles of children with perennial
AR.
2. Materials and methods
2.1. Patients
A total of 95 patients aged 6e13 years were screened, and
among these patients 60 fulfilled the inclusion criteria for
the study. All had perennial AR for more than 1 year, were
allergic to house dust mites, which was confirmed by a
positive reaction to mite-specific IgE (MAST score 2), and
total nasal symptoms scores 5. Exclusion criteria included
any of the following: moderate and severe asthma;
participation in other clinical trials within 1 month prior to
screening; ingestion of any food supplements containing
probiotics within 3 days of study entry; a history of hyper-
sensitivity to the study drug; rhinitis medicamentosa; prior
or recent immunotherapy and renal impairment. In addi-
tion, usage of short-acting antihistamines (intranasal or
systemic) and decongestants (intranasal or systemic) within
3 days; leukotriene receptor antagonist and any herb
treatment within 7 days; long-acting antihistamines within
10 days; corticosteroids (intranasal or inhaled) and intra-
nasal sodium cromoglycate within 2 weeks and systemic
corticosteroids within 1 month of study commencement
also precluded entry into this study. This study was
approved by the Institutional Ethics Committee of Taichung
Veterans General Hospital (Taichung, Taiwan; number
S10239). Written informed consent was obtained from the
parents or guardians of the patients prior to commencing
the study.
2.2. Study design
This study was a parallel (note: this is the only section of
the paper in which the study is called a parallel study),
double-blind, randomized, placebo-controlled 12-week
trial which investigated the effect of LP (HF.A00232) (TTY
Biopharm Company Limited, Taipei, Taiwan) as a supple-
mentary agent to levocetirizine in children with perennial
AR. The probiotics and placebo capsules were stored at
2e8C. The protocol is illustrated in Figure 1. A
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Figure 1 Description of enrolled participants and general schematic representation of the study.
Effect of L. paracasei in children 183comprehensive medical and allergy history was obtained
from all participants at the initial screening visit (Week 1)
and blood samples for mite-specific IgE were obtained.
Daily symptom diaries were given to each patient with in-
structions to record all symptoms starting 7 days prior to
treatment. Detailed medication histories were reviewed to
ensure that participants had not taken any prohibited
drugs.
At Week 0, the 60 patients were randomized into two
groups, whereby 28 participants were given levocetirizine
plus placebo (maltodextrin capsule) and 32 participants
received levocetirizine plus LP (HF.A00232) (5  109 cfu/
capsule) for the first 8 weeks, with a shift to usage of lev-
ocetirizine as rescue treatment during the last 4 weeks.
At each visit, we retrieved patients’ symptom diaries,
conducted physical examinations (including measurement
of blood pressure, heart rate, and temperature), and
administered the Pediatric Rhinoconjunctivitis Quality of
Life Questionnaire (PRQLQ). In addition, blood samples
were taken for evaluation of IL-4, IFN-g, IL-10, and TGF-b
at baseline, Week 8, and Week 12 (Figure 1).2.3. Daily symptom diary
The widely used total symptom score (TSS) and nasal total
symptom score (NTSS) were applied in our study.5 A diary
card was given to each patient 7 days prior to the start of the
study. Patients and their parents were required to record the
patient’s daily symptoms, which included four nasal symp-
toms (nasal itching, sneezing, rhinorrhea, and nasal
congestion), three eye symptoms (conjunctival itching,
conjunctival hyperemia, and eye tearing), and two throat
symptoms (throat itching and coughing). Symptoms were
evaluated using a four-point scale as follows: zero (noneZ
symptoms not noticeable); one (mild Z symptoms notice-
able but not bothersome); two (moderate Z symptoms
noticeable and bothersome some of the time); and three
(severeZ symptoms bothersome most of the time). The TSS
was the sum of the nine recorded symptom scores; and the
NTSS, eye TSS (ETSS), and throat TSS (TTSS) being the sum of
the recorded nasal, eye, and throat symptom scores. The
baseline symptom scores were calculated as themean of the
daily scores during the baseline study period of 7 days. Sub-
sequently, these scores were based on scores for thepreceding 28 days at Week 0, Week 4, Week 8, and Week 12,
respectively. In addition, daily diary records of LP
(HF.A00232)/placebo and levocetirizine usewere kept by the
participants and checked at each follow-up visit. Unused
capsuleswere counted and retrieved at return Visit 3, Visit 4,
and Visit 5.
2.4. Pediatric Rhinoconjunctivitis Quality of Life
Questionnaire
The modified PRQLQ, as previously described,16 has 23
questions in five domains: nasal symptoms, ocular symp-
toms, practical problems, other symptoms, and activity
limitations. Each item was scored using a seven-point scale
from zero to six, with zero representing no impairment and
six representing maximum impairment. The participants
were asked to complete the questionnaire with assistance
from their parents at Week 0, Week 4, Week 8, and
Week 12.
2.5. Measurement of peripheral blood mite-specific
IgE, IL-4, IFN-g, IL-10, and TGF-b
Total serum mite-specific IgE was measured by fluo-
roimmunoassay using the Hitachi MAST system (Hitachi
Chemical Diagnostics, Mountain View, CA, USA). Peripheral
blood was also sampled and IL-4, IFN-g, IL-10, and TGF-b
were measured by enzyme-linked immunosorbent assay
(ELISA) using commercially available kits (BD Biosciences,
San Diego, CA, USA).
2.6. Statistical analysis
For demographic and baseline characteristics, the cate-
gorical data were tabulated by frequency and percentage.
The Chi-square test was used to compare the categorical
data between the two study groups. Continuous variables
were summarized by mean, medium, minimum, maximum,
and standard deviation. The differences between the two
study groups were compared by using the unpaired t test,
and differences between visits in the two groups were
compared by paired t test. In all tests, p < 0.05 was
considered to be statistically significant.
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A total of 95 patients were enrolled during the screening
visit. Of these, 60 fulfilled the inclusion criteria and
completed the study. Patients were randomized into the
levocetirizine (5 mg) plus LP (HF.A00232) group (n Z 32)
and the levocetirizine (5 mg) plus placebo group (n Z 28)
on Day 1 of Week 0. We also subdivided each group ac-
cording to the use of rescue levocetirizine between Day 57
and Day 66 [subgrouped as LP (HF.A00232)-1 and placebo-1]
or not [subgrouped as LP (HF.A00232)-0 and placebo-0]. The
demographic and baseline data of the LP (HF.A00232) and
placebo groups are summarized in Table 1; and those of the
subgroups are summarized in Table 2. In both groups, as
well as their subgroups, participants had similar de-
mographic profiles with regard to age, sex, height, and
weight. Compliance with regard to levocetirizine use in the
first 8 weeks in these groups was 100%, and there was no
statistical difference in rescue levocetirizine usage from
Week 9 to Week 12 or from Week 10.5 to Week 12. There
were no differences in the baseline TSS, NTSS, TTSS, ETSS,
and PRQLQ scores and various cytokine profiles between
the groups. Patients in the LP (HF.A00232) and placebo
groups used fewer levocetirizine capsules from Week 9 to
Week 12 than from Week 1 to Week 8 (p < 0.001). The LP
(HF.A00232)-0 and placebo-0 subgroups used even fewer
rescue levocetirizine capsules than the LP (HF.A00232)-1
and placebo-1 subgroups from Week 9 to Week 12
(pZ 0.0005 and pZ 0.00002, respectively) and from Week
10.5 to Week 12 (pZ 0.0007 and pZ 0.0004, respectively).
In the LP (HF.A00232) and placebo groups, along with the
four subgroups, all scores including TSS, NTSS, ETSS, and
TTSS were lower (p < 0.001) at Visits 3, 4, and 5 compared
with the baseline; however, there was no difference be-
tween the two groups in TSS, NTSS, ETSS, or TTSS
throughout the study (Figure 2A).
The overall PRQLQ scores were lower in Visit 3, Visit 4,
and Visit 5 compared with those in Visit 2 in both groups (all
p < 0.0001), as shown in Figure 2B, with no statisticallyTable 1 Baseline demographic characteristics of the study pop
LP HF.A00232 (total) (
Age (y) 9.5  2.0
Sex (male/female) 25:7
Height (cm) 134.6  11.8
Weight (kg) 34.6  13.3
Levocetirizine use: 1e8 wk (%) 100
Levocetirizine use: 9e12 wk 44.18  35.47
Levocetirizine use: 10.5e12 wk 43.35  38.53
TSS 16.25  7.02
NTSS 5.27  1.87
PRQLQ 64.03  23.35
IL-4 (pg/mL) 14.36  31.85
IFN-g (pg/mL) 37.07  32.78
IL-10 (pg/mL) 25.44  37.58
TGF-b (pg/mL) 1063.56  762.17
IFN-g Z interferon gamma; IL-4 Z interleukin-4; IL-10 Z interleukin
score; PRQLQ Z Pediatric Rhinoconjunctivitis Quality of Life Questi
symptoms score.significant differences between the six groups. In the LP
(HF.A00232) group, there was a significant decrease in
symptom scores (p Z 0.003) from Week 5 to Week 8 and
from Week 9 to Week 12, but not in the placebo group. The
subgroup LP (HF.A00232)-1 had lower PRQLQ scores in Visit
5 than in Visit 4 (36.05  21.08 vs. 45.36  25.03,
p Z 0.014). Although the subgroup LP (HF.A00232)-0 also
had lower PRQLQ scores in Visit 5 than in Visit 4
(22.33  12.57 vs. 35.44  26.26), the difference did not
reach statistical significance (p Z 0.06). Nevertheless, the
LP (HF.A00232)-0 subgroup had lower PRQLQ scores at Visit
5 than the LP (HF.A00232)-1 and placebo-0 groups
(p Z 0.046 and p Z 0.049, respectively).
The mean change of individual parameters in PRQLQ
scores was analyzed and comparison between the LP
(HF.A00232) and placebo groups from baseline to Week 12
revealed that the LP (HF.A00232) group had lower scores
for individual symptoms of sneezing (1.9  1.5 vs.
0.9  1.2, p Z 0.005), itchy nose (2.0  1.5 vs.
1.2  1.4, p Z 0.040), and swollen puffy eyes than the
placebo group (0.9  1.4 vs. 0.0  1.8, p Z 0.038).
Figure 3 shows the percentage of change in serum
cytokine levels over the study period in the LP (HF.A00232)
and placebo groups. There were no significant changes in
cytokine levels between these two groups.
No serious adverse events were recorded in either group.
The vital signs and physical examination of all systems
revealed no differences between these two groups.4. Discussion
This study was a double-blind, randomized, placebo-
controlled trial designed to specifically explore the ef-
fects of LP (HF.A00232) on AR as a supplementary agent to
regular levocetirizine use from Week 1 to Week 8, with a
shift to levocetirizine as rescue treatment from Week 9 to
Week 12. We did not observe any add-on effect of LP
(HF.A00232) as a supplement to levocetirizine in managingulation.
n Z 32) Placebo (total) (n Z 28) p
9.3  2.3 0.73
22:6 0.97
137.9  14.6 0.34
34.3  12.1 0.92
100
36  37.22 0.43
32.63  38.57 0.15
18.80  9.00 0.13
5.62  1.83 0.46
72.65  23.80 0.09
15.87  17.66 0.44
48.44  36.79 0.13
29.80  33.35 0.32
1260.39  868.51 0.20
-10; LP Z Lactobacillus paracasei; NTSS Z nasal total symptoms
onnaire; TGF-b Z transforming growth factor-beta; TSS Z total
T
a
b
le
2
B
a
se
li
n
e
d
e
m
o
gr
a
p
h
ic
ch
a
ra
ct
e
ri
st
ic
s
a
n
d
d
ru
g
u
sa
ge
s
o
f
th
e
st
u
d
y
p
o
p
u
la
ti
o
n
su
b
gr
o
u
p
s.
LP
H
F.
A
00
23
2
w
it
h
re
sc
u
e
le
vo
ce
ti
ri
zi
n
e
u
se
fr
o
m
D
a
y
57
to
D
a
y
66
[L
P
(H
F.
A
00
23
2-
1)
]
P
la
ce
b
o
w
it
h
re
sc
u
e
le
vo
ce
ti
ri
zi
n
e
u
se
fr
o
m
D
a
y
57
to
D
a
y
66
(P
la
ce
b
o
-1
)
p
LP
H
F.
A
00
23
2
w
it
h
o
u
t
re
sc
u
e
le
vo
ce
ti
ri
zi
n
e
u
se
fr
o
m
D
a
y
57
to
D
a
y
66
[L
P
(H
F.
A
00
23
2-
0)
]
P
la
ce
b
o
w
it
h
o
u
t
re
sc
u
e
le
vo
ce
ti
ri
zi
n
e
u
se
fr
o
m
D
a
y
57
to
D
a
y
66
(P
la
ce
b
o
-0
)
p
A
ge
(y
)
9.
48

2.
06
9.
38

2.
15
0.
45
9.
88

2.
33
9.
48

2.
38
0.
34
Se
x
(m
a
le
/f
e
m
a
le
)
17
:6
13
:3
0.
71
8:
1
9:
3
0.
60
H
e
ig
h
t
(c
m
)
13
5.
1

13
.8
2
13
6.
6

13
.7
3
0.
37
13
4.
6

11
.4
1
13
8.
0

15
.6
4
0.
28
W
e
ig
h
t
(k
g)
35
.1

15
.6
8
32
.0

9.
74
0.
25
35
.4

11
.9
2
35
.9

13
.8
1
0.
46
Le
vo
ce
ti
ri
zi
n
e
u
se
:
1e
8
w
k
(%
)
10
0
10
0
10
0
10
0
Le
vo
ce
ti
ri
zi
n
e
u
se
:
9e
12
w
k
(%
)
58
.8
3

30
.2
0
52
.3
8

33
.8
7
0.
28
16
.7
9

28
.2
7*
8.
93

19
.3
5y
0.
22
Le
vo
ce
ti
ri
zi
n
e
u
se
:
10
.5
e
12
w
k
(%
)
55
.3
9

33
.4
5
46
.2
1

39
.7
1
0.
31
20
.4
8

38
.6
2*
*
11
.9
2

25
.8
0z
0.
27
*p
Z
0.
00
05
7;
**
p
Z
0.
00
87
,
th
e
co
m
p
ar
is
o
n
b
e
tw
e
e
n
LP
(H
F.
A
00
23
2)
-1
a
n
d
LP
(H
F.
A
00
23
2)
-0
.
yp
Z
0.
00
02
8
zp
Z
0.
00
48
,
th
e
co
m
p
ar
is
o
n
b
e
tw
e
e
n
P
la
ce
b
o
-1
a
n
d
P
la
ce
b
o
-0
.
LP
Z
La
ct
o
b
a
ci
ll
u
s
p
a
ra
ca
se
i.
Effect of L. paracasei in children 185AR in the first 8 weeks. Although no differences in NTSS,
TTSS, ETSS, or TSS scores between the LP (HF.A00232) and
placebo groups were noted throughout the study, several
individual symptoms, including sneezing, itchy nose, and
swollen puffy eyes, showed significant improvement at the
end of this study (Visit 5) in the LP (HF.A00232) group. This
group also had significant improvement in overall PRQLQ
scores towards the latter part of the study period. LP
(HF.A00232) may thus continuously improve the life quality
of children with AR, with an approximately 56% reduction in
levocetirizine usage.
In the latter part of this study, that is, from Week 9 to
Week 12, levocetirizine was used as a rescue medicine. To
exclude the effect of daily levocetirizine usage from Week
1 to Week 8, we subdivided participants according to their
levocetirizine use from Day 57 to Day 66. There were no
differences in symptom scores of those who discontinued
levocetirizine during these 10 days, subgrouped as LP
(HF.A00232)-0 and placebo-0 in our study; however, PRQLQ
scores were lower at Visit 5 in the LP (HF.A00232)-0 sub-
group than the placebo-0 subgroup (p Z 0.049). In addi-
tion, there were no differences in symptom scores or
PRQLQ scores in these two subgroups between Visit 4 and
Visit 5, although the p-value of the difference in PRQLQ
scores between Visit 4 and Visit 5 in the LP (HF.A00232)-
0 subgroup was 0.006. This result may be due to the small
cohort in the present study.
By contrast, the subgroup LP (HF.A00232)-1, which used
rescue levocetirizine from Day 57 to Day 66, and also used
more rescue levocetirizine in the following period (from
Week 10.5 to Week 12), as shown in Table 2, did have
progressively lower PRQLQ scores in the latter part of the
study. Such improvement did not occur in the placebo-1 or
LP (HF.A00232)-0 subgroups. This result can be explained as
the synergistic effect of LP (HF.A00232) and levocetirizine,
which implies that LP (HF.A00232) can be a supplement to
levocetirizine in AR management. However, long-term
studies with large cohorts are needed to confirm this result.
Perennial AR can cause bothersome symptoms all year
round, which necessitate long-term usage of medication
with consideration of associated side effects. In addition,
only a few types of medication are available and considered
safe for use in children. Increasing evidence has shown that
human gut flora is a major factor in health, and several
studies have demonstrated the beneficial effect of Lacto-
bacillus in atopic diseases.6,10,14,15 Table 3 provides a
summary of some pediatric clinical trials that were per-
formed to evaluate the effect of probiotics on AR. Gio-
vannini et al7 reported that children receiving fermented
milk containing Lactobacillus casei had a 33% lower occur-
rence of rhinitis episodes as compared with the control
group in a 12-month study. Studies on Lactobacillus LP33
have also demonstrated its beneficial effects on AR symp-
toms with no serious adverse side effects.14,15 However,
other studies have found no significant difference in
symptom scores between the control and intervention
groups.10,11 Our study differs in that it was specifically
conducted to explore the supplementary effect of LP
(HF.A00232) in children with AR only, excluding possible
confounding factors such as coexisting asthma or usage of
medication such as steroids, leukotriene receptor antago-
nists, or antihistamines other than those administered
Figure 2 (A) NTSS, TTSS, ETSS, and TSS scores in the LP (HF.A00232), LP (HF.A00232)-0, LP (HF.A00232)-1, placebo, placebo-0,
and placebo-1 groups over the 12-week study period. (B) Change in overall PRQLQ scores in all groups over the 12-week study
period. ETSS Z eye total symptoms score; LP Z Lactobacillus paracasei; NTSSZ nasal total symptoms score; PRQLQ Z Pediatric
Rhinoconjunctivitis Quality of Life Questionnaire; TSS Z total symptoms score; TTSS Z throat total symptoms score.
186 W.-Y. Lin et alduring the study. There was one other study which inves-
tigated levocetirizine use10; however, it was an open-
labeled trial. The results showed significant improvement
in TSS and NTSS, but not PRQLQ scores, in their probiotic
group.IL-4     INF- IL-10      TGF-
Figure 3 Change in serum cytokine levels from baseline in
the placebo group and the LP (HF.A00232) group over the 12-
week study period. LP Z Lactobacillus paracasei.It is known that in the local gastrointestinal milieu,
probiotics provide maturational signals for gut-associated
lymphoid tissue, downregulate inflammatory mediators,
and thus act to balance the generation of pro- and anti-
inflammatory cytokines. Additionally, probiotics act to
stabilize the gut microbial environment and intestinal
permeability barrier, enhance the degradation, and alter
immunogenicity of enteral antigens.17,18 Probiotics are also
postulated to be one of the factors to induce oral tolerance
by boosting T-regulatory (Treg) cell activity.19 The mecha-
nism of action of probiotics is thus multi-faceted and each
probiotic type may confer specific functions on its host,
including different cytokine stimulation profiles. Bifido-
bacterium bifidum, Bifidobacterium infantis, and Lacto-
bacillus lactis have been demonstrated to reduce T-helper
(Th)2 cytokines and induce IL-10 production in different
peripheral blood mononuclear cell cultures.20 In another
study, Lactobacillus reuteri induced proinflammatory and
Th1 cytokine production.21 Thus, the specific effects of
various probiotics on Th1-, Th2-, or Treg-associated cyto-
kines differ widely and remain to be clarified. The L. par-
acasei strain (HF.A00232) has been found to have
immunomodulatory effects in in vitro studies. In an un-
published cellular study, HF.A00232 promoted Th1
Table 3 Summary of published studies of probiotic effects on pediatric perennial allergic rhinitis.
Refs Patients
(n)
Patient
age (y)
Types of AR Intervention Administered AR
medication
Study
duration
Outcomes
Lue et al10 (2012) 63 7e12 Perennial Lactobacillus johnsonii EM1
(1  1010 cfu) prior to
bedtime
Levocetirizine 24 wk An open-labeled trialLower
TSS (p < 0.05) and PRQLQ
score (p < 0.05) in both
groups but no significant
difference between the two
groups
Significant increase in IFN-
g, IL-10, and decreased IL-4
in both groups, increased
TGF-b in one group
Lin et al11 (2013) 199 Children Perennial Lactobacillus salivarius
(4  109 cfu), daily
e 3 mo No significant difference in
rhinitis symptoms
Chen et al12 (2010) 105 6e12 Perennial Lactobacillus gasseri A5
(>2  109 cfu), bid
e 8 wk Improved AR symptoms
(p Z 0.01)
Significant decrease in TNF-
a, IFN-g, IL-12, and IL-13
Giovannini
et al7 (2007)
187 2e5 Perennial and
seasonal
Lactobacillus casei
(1  1010cfu) in milk
e 12 mo Lower number of annual
rhinitis episodes in
intervention group, mean
difference (95% CI), 1.6
(3.15 to 0.05)
Peng et al14 (2005) 90 >5 Perennial Lactobacillus paracasei-33
(1  1010cfu), daily
e 30 d Lower PRQLQ score
(frequency p < 0.0001, level
of bother p Z 0.004)
Wang et al15 (2004) 80 >5 Perennial Lactobacillus paracasei-33
(2  109cfu) in fermented
milk daily
e 30 d Lower PRQLQ score
(frequency with p Z 0.037,
level of bother p Z 0.022)
This study (2013) 60 6e13 Perennial Lactobacillus paracasei-
HF.A00232 (5  109cfu) prior
to bedtime
Levocetirizine 12 wk Significant decrease in
PRQLQ scores after
discontinuing regular
levocetirizine use
Decreased individual
symptoms of sneezing
(p Z 0.005), itchy nose
(p Z 0.040), and swollen
puffy eyes (p Z 0.038)
ARZ allergic rhinitis; CIZ confidence interval; IFN-gZ interferon gamma; ILZ interleukin; PRQLQZ Pediatric Rhinoconjunctivitis Quality of Life Questionnaire; TGF-bZ transforming
growth factor-beta; TNF-a Z tumor necrosis factor-alpha.
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188 W.-Y. Lin et alresponse, and in an animal study, it decreased IgE levels
and increased IFN-g secretion. However, in our study the
results of cytokine assays were inconclusive. Analysis of the
change of serum IL-4, IFN-g, IL-10, and TGF-b levels from
baseline revealed no statistically significant differences
between the levocetirizine plus LP (HF.A00232) group and
the levocetirizine plus placebo group.
The main limitation of this study is the short study
period. Therefore, we could not evaluate the placebo ef-
fect, which may last up to 12 months, on TSS, NTSS, TTSS,
ETSS, PRQLQ scores, and cytokine profiles. Another concern
is that the use of regular levocetirizine (Weeks 0e8) and its
rescue usage (Weeks 9e12) could mask the probiotic effect,
although there were no significant differences in either
group in regular (100% vs. 100%) or rescue (44.18% vs. 36%)
levocetirizine use. We did try to exclude the levocetirizine
effect from our analysis by subdividing patients who dis-
continued levocetirizine for at least 10 days in the latter
part of this study.
In summary, supplementary treatment of LP (HF.A00232)
with levocetirizine in the first 8 weeks of our study provided
no additional benefit in the levocetirizine plus placebo
group. However, in the last 4 weeks of the study period,
when LP (HF.A00232) alone was given with levocetirizine as
a rescue medication, improvement in overall PRQLQ scores
was noted. There was significantly greater improvement in
individual symptoms such as sneezing, itchy nose, and
swollen eyes in the LP (HF.A00232) group than in the pla-
cebo group at the end of this study. The results of the
cytokine analysis were inconclusive. Long-term studies with
large cohorts are needed to confirm the beneficial effects
of probiotics, including L. paracasei.
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